Nocebo Hypothesis Cognitive Behavioral Therapy for Functional Neurological Symptom Disorder (Motor Type): A Pilot Randomized Controlled Trial
Movement Disorders · 2025-07 · 40 (7) · 1331-1342
DOI: 10.1002/mds.30195 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Movement Disorders, online erschienen am 12.05.2025. Verfasst von Matt Richardson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychological Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand. Hauptthemen laut MEDLINE: Cognitive Behavioral Therapy, Nocebo Effect, Conversion Disorder. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health Research Council of New Zealand.
Abstract (Originalsprache)
Background
A previous case series showed that Nocebo Hypothesis Cognitive Behavioral Therapy (NH‐CBT) is a promising treatment for Functional Neurological Symptom Disorder (FNSD).
Objectives
To further evaluate the potential efficacy of NH‐CBT in participants with FNSD (motor type).
Methods
This phase IIb pilot, randomized, parallel group trial compared the efficacy of NH‐CBT (n = 20) with an active control condition (n = 19). Self‐report scales of motor and other physical symptoms, psychological variables, and blinded assessor ratings of participants' mobility were administered at baseline, and at 8‐ and 16‐week follow‐ups. The primary outcome and endpoint of this trial was the Physical Functioning scale of the Short Form‐36 Health Questionnaire (SF‐36 PF) at the end of treatment.
Results
Regarding the primary endpoint (SF‐36 at the end of treatment), we did not identify a significant between‐group effect ( d = 0.21, 95% CI: −0.42‐0.84). Significant between‐group effects in favor of NH‐CBT were identified for several secondary outcomes (motor symptoms: d = 0.67, 95% CI: 0.02–1.32; mobility: d = 0.70, 95% CI: 0.05–1.35; symptom perception “concern”: d = 0.66, 95% CI: 0.01–1.31). Changes in outcomes within the NH‐CBT group showed large effects ( d > 0.80) for the primary outcome (SF‐36 PF) and the majority of secondary measures post‐treatment. A significantly greater proportion of NH‐CBT (85%) than control participants (47%) showed full recovery of motor symptoms ( P = 0.013).
Conclusions
NH‐CBT resulted in large within‐group effects on the primary outcome as well as the majority of secondary measures in the NH‐CBT group and a greater proportion of fully recovered participants compared with an active control treatment. These promising findings warrant a definitive trial. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychological Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
- Puāwai Rehabilitation Unit, Wakari Hospital, Dunedin, New Zealand.
- Department of Psychology, Utah State University, Logan, Utah, USA.
- School of Psychology and Public Health, La Trobe University, Melbourne, Victoria, Australia.
ORCID-Profile: Matt Richardson, Maria Kleinstäuber, Dana Wong
Förderung
- Health Research Council of New Zealand
Zitieren
APA
Richardson, M., Kleinstäuber, M., & Wong, D. (2025). Nocebo Hypothesis Cognitive Behavioral Therapy for Functional Neurological Symptom Disorder (Motor Type): A Pilot Randomized Controlled Trial. Movement Disorders, 40(7), 1331-1342. https://doi.org/10.1002/mds.30195
Vancouver
Richardson M, Kleinstäuber M, Wong D. Nocebo Hypothesis Cognitive Behavioral Therapy for Functional Neurological Symptom Disorder (Motor Type): A Pilot Randomized Controlled Trial. Movement Disorders. 2025;40(7):1331-1342. doi:10.1002/mds.30195
BibTeX
@article{Richardson2025,
author = {Richardson, Matt and Kleinstäuber, Maria and Wong, Dana},
title = {Nocebo Hypothesis Cognitive Behavioral Therapy for Functional Neurological Symptom Disorder (Motor Type): A Pilot Randomized Controlled Trial},
journal = {Movement Disorders},
year = {2025},
volume = {40},
number = {7},
pages = {1331--1342},
doi = {10.1002/mds.30195}
}
EUVIMED